SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is sharply lower after its mixed quarterly report showed strong revenue growth and user acquisition but also a net loss driven by increased credit loss provisions and a cautious near-term forecast. The community is debating the long-term viability of the buy now, pay later model amidst concerns over credit risk and the company's path to profitability.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL Inc. is trending due to a steep stock decline after its Galleri cancer test missed a primary statistical endpoint in a UK trial. This has sparked a divided community discussion, with some viewing the sell-off as an overreaction given positive underlying detection data and strong financials, while others emphasize the trial's miss and broader biotech sector risks.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO is trending as its dedicated community celebrates its 1-year anniversary, rallying around its unique "infinite money glitch" model that automatically rewards holders with Solana and continues to roll out new features and liquidity pools.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is trending as the community speculates on its long-term potential, driven by recent token burns and its expanding utility as a multi-chain 'universal gas token.' Many users are actively discussing the crypto's 'move-to-earn' incentives and new ecosystem features, expressing strong optimism for its future growth despite current price levels.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending due to its transformative all-stock merger with Valaris, creating a dominant offshore drilling powerhouse with an expanded fleet and substantial backlog. Community discussion, despite initial earnings reports, is focused on the adjusted positive performance, significant debt reduction efforts, and the strategic advantages of the acquisition in a resurgent energy market, with many anticipating a short squeeze.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is gaining attention following news of institutional interest through potential Grayscale and Bitwise ETF filings, a significant token inflation reduction, and its collaboration with NVIDIA for AI development. The community is actively accumulating, viewing its advanced AI integration and growing 'Intents' cross-chain utility as strong catalysts for a substantial rally.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending amid reactions to a new public stock offering and a contingent royalty funding agreement, fueling community debate about significant shareholder dilution versus securing critical capital for its lead prostate cancer candidate's potential commercialization and to strengthen its financial runway.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic (LUNC) is trending amid intense community debate following the Do Kwon sentencing, with proponents anticipating a resurgence fueled by ongoing Binance burns and new ecosystem initiatives, contrasting with persistent skepticism about its long-term viability.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly anticipates the imminent resubmission of its Biologics License Application for Deramiocel, a Duchenne muscular dystrophy treatment, driving optimism for a significant short squeeze. Investors are closely watching for updates on the company's StealthX vaccine platform and broader FDA regulatory consistency, viewing CAPR as a promising, undervalued biotech in the rare disease space.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences (VTYX) is trending amid intense speculation that Eli Lilly's $14 per share acquisition offer dramatically undervalues the company, prompting widespread anticipation of a bidding war from other major pharmaceutical players. Investors are actively discussing the potential for significantly higher bids, citing VTYX's promising NLRP3 inhibitor pipeline for cardiometabolic and neuroinflammatory diseases and drawing comparisons to recent aggressive biotech M&A.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56%

Upstream Bio (NASDAQ:UPB) reported top-line results from its Phase II VALIANT trial evaluating verekitug in adults with severe asthma, highlighting statistically significant reductions in annualized...

Upstream Bio (NASDAQ:UPB) Sees Large Volume Increase - Here's Why

Upstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume - Here's What Happened...

Upstream Bio (NASDAQ:UPB) Trading Down 10.3% - Time to Sell?

Upstream Bio (NASDAQ:UPB) Trading Down 10.3% - Here's Why...

Upstream Bio (NASDAQ:UPB) Shares Gap Down - Here's Why

Upstream Bio (NASDAQ:UPB) Shares Gap Down - Should You Sell...

Biotech Stocks To Add to Your Watchlist - February 11th

Moderna, Danaher, Vertex Pharmaceuticals, Medpace, and Upstream Bio are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies...

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Upstream Bio shares rise after Phase 2 data show its asthma drug cut attacks by up to 56% and improved lung function. The company plans late-stage trials.read more...

<ul class="summary-bullets"><li>Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile.</li><li>Verekitug reduced asthma attacks by 56% with 100 mg, and 39% with 400 mg compared to placebo.</li><li>Upstream has begun planning Phase 3 studies.&nbsp;</li></ul>Shares of Upstream Bio Inc. (UPB) crashed more than 40% on Wednesday despite the company announcing positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.<h2 class="st-heading-2">Details Of The Test</h2>Verekitug, which targets the thymic stromal lymphopoietin (TSLP) receptor, reduced annual asthma attacks by 56% with 100 mg and 39% with 400 mg compared to placebo. Patients also showed improved lung function. Patients received Verekitug every 12 weeks for the 100 mg dose or every 24 weeks for the 400 mg dose.&nbsp;Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile. More than 90% of eligible participants have enrolled in the VALOUR long-term extension trial to further assess the treatment’s durability.“We intend to rapidly advance verekitug into Phase 3 trials in severe asthma and CRSwNP. In parallel, we also continue to progress verekitug in our ongoing Phase 2 VENTURE trial in patients with COPD, where we have enrolled more than 60% of patients to date,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio.&nbsp;<h2 class="st-heading-2">Phase 3 Studies Update</h2>Upstream Bio structured the VALIANT trial with endpoints intended to support potential approval filings, and has begun planning Phase 3 studies in severe asthma and CRSwNP, with registrational trials expected after regulatory discussions.The results reportedly aligned exactly with Amgen’s (AMGN) Tezspire in effectiveness. The drug requires 210 milligrams every four weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/UPB">UPB</a> on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said the market reaction was ‘unwarranted’.<stembedurl>https://stocktwits.com/stjernerogvann/message/644653420</stembedurl>Another user saw a buying opportunity.<stembedurl>https://stocktwits.com/lordBrian/message/644666591</stembedurl>Year-to-date, the stock has declined more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did UPB Stock Plunge 40% Today?

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

Equity

Upstream Bio (NASDAQ:UPB) Stock Price Up 9.4% - Here's What Happened

Upstream Bio (NASDAQ:UPB) Stock Price Up 9.4% - What's Next...

Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Rating of "Moderate Buy" from Analysts

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat Ratings...

Upstream Bio (NASDAQ:UPB) Stock Price Down 4.6% - Should You Sell?

Upstream Bio (NASDAQ:UPB) Trading Down 4.6% - Should You Sell...

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Current Price	$8.54
Prev Close	$8.29
Open	$8.32
Dividend Yield	0.00%
50-Day Moving Average	$27.33
Beta	1.20
Avg. Volume	623,575.05
PE Ratio	-3.63

52-Week High	$33.68
52-Week Low	$5.14
Market Capitalization	$447.98M
EPS (Annual)	-$1.43
Price to Book	1.18
Revenue Per Employee	$45,576.92

UPB
Upstream Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UPB News

UPBUpstream Bio Inc.